← Back to LibraryPractice Questions →

Paraneoplastic Syndromes: Hypercalcemia, SIADH, Lambert-Eaton, and Cushing Syndrome

Oncology11 min read2,169 wordsadvanced
Updated 4/2/2026
Contents

Paraneoplastic syndromes are clinical disorders caused by tumor-secreted factors that affect distant organ systems, distinct from direct tumor effects or metastases. These syndromes occur in 10-20% of cancer patients and may precede, coincide with, or follow cancer diagnosis.

[KEY_CONCEPT] Four major paraneoplastic syndromes have significant clinical impact:

Hypercalcemia of Malignancy

Parathyroid hormone-related protein (PTHrP) secretion accounts for 80% of cases, primarily from squamous cell carcinomas. PTHrP activates parathyroid hormone receptors, increasing calcium reabsorption and bone resorption. Osteolytic metastases comprise 20% of cases, typically from breast, lung, kidney, or multiple myeloma.

Syndrome of Inappropriate ADH (SIADH)

Ectopic ADH secretion leads to water retention and hyponatremia. Small cell lung cancer (SCLC) accounts for 75% of cases. ADH inappropriately increases water reabsorption in collecting ducts despite normal or low serum osmolality.

Lambert-Eaton Myasthenic Syndrome (LEMS)

Anti-voltage-gated calcium channel (VGCC) antibodies impair presynaptic acetylcholine release at neuromuscular junctions. SCLC is associated in 50-60% of cases. P/Q-type calcium channels are primarily affected.

Cushing Syndrome

Ectopic ACTH secretion from neuroendocrine tumors leads to cortisol excess. SCLC, pancreatic islet cell tumors, and carcinoid tumors are common sources. Rapid onset distinguishes it from pituitary Cushing disease.

[HIGH_YIELD] Recognition of paraneoplastic syndromes may lead to earlier cancer diagnosis and impacts treatment decisions, as syndrome resolution often parallels tumor response to therapy.

Clinical manifestations vary significantly based on the specific syndrome and underlying malignancy.

Hypercalcemia of Malignancy

Constitutional symptoms dominate presentation:

  • Neurologic: Confusion, lethargy, coma, depression
  • Gastrointestinal: Nausea, vomiting, constipation, anorexia
  • Renal: Polyuria, polydipsia, nephrogenic diabetes insipidus
  • Cardiac: Shortened QT interval, arrhythmias

[CLINICAL_PEARL] "Stones, bones, groans, and psychiatric moans" remains a useful mnemonic, though neurologic symptoms often predominate in malignancy-associated hypercalcemia.

SIADH

Hyponatremia severity determines clinical presentation:

  • Mild (130-134 mEq/L): Often asymptomatic
  • Moderate (125-129 mEq/L): Headache, nausea, confusion
  • Severe (<125 mEq/L): Seizures, coma, respiratory arrest

Onset rapidity influences symptom severity more than absolute sodium level.

Lambert-Eaton Myasthenic Syndrome

Progressive proximal muscle weakness beginning in lower extremities:

  • Motor symptoms: Difficulty rising from chairs, climbing stairs
  • Autonomic features: Dry mouth (90%), constipation, erectile dysfunction
  • Post-exercise facilitation: Temporary strength improvement after brief exercise (pathognomonic)
  • Reduced/absent reflexes: Unlike myasthenia gravis

[HIGH_YIELD] Ocular and bulbar muscles are typically spared in LEMS, distinguishing it from myasthenia gravis.

Ectopic Cushing Syndrome

Rapid-onset features distinguish from pituitary disease:

  • Metabolic: Severe hypokalemia, hyperglycemia, metabolic alkalosis
  • Physical: Proximal myopathy, peripheral edema
  • Psychiatric: Depression, psychosis, cognitive impairment
  • Classic cushingoid features (moon facies, buffalo hump, striae) are often absent due to rapid progression
SyndromeKey Clinical FeaturesTimeline
HypercalcemiaNeurologic symptoms, polyuriaDays to weeks
SIADHProgressive hyponatremia, confusionDays to weeks
LEMSProximal weakness, post-exercise facilitationMonths
CushingMetabolic disturbances, myopathyWeeks to months

Systematic diagnostic evaluation requires biochemical confirmation followed by malignancy screening.

Hypercalcemia Workup

Elevated Total or Ionized Calcium ↓ Measure PTH Level ↓ Suppressed PTH (<20 pg/mL) ↓ Measure PTHrP ↓ PTHrP Elevated → Malignancy-associated PTHrP Normal → Evaluate for:

  • Granulomatous disease (1,25-dihydroxyvitamin D)
  • Vitamin D intoxication (25-hydroxyvitamin D)
  • Other causes (sarcoidosis, medications)

[KEY_CONCEPT] PTH suppression with elevated calcium is the hallmark of malignancy-associated hypercalcemia.

SIADH Diagnostic Criteria

Essential criteria (all must be present):

  • Serum sodium <135 mEq/L
  • Serum osmolality <280 mOsm/kg
  • Urine osmolality >100 mOsm/kg (typically >300)
  • Urine sodium >30 mEq/L
  • Clinical euvolemia
  • Normal thyroid, adrenal, and renal function
LEMS Diagnostic Studies

Electromyography findings:

  • Low-amplitude compound muscle action potentials (CMAPs)
  • 100% increment in CMAP amplitude with 20-50 Hz stimulation

  • Post-exercise facilitation lasting 2-5 minutes

Anti-VGCC antibodies: Present in 85-95% of cases

Cushing Syndrome Evaluation

Suspected Ectopic ACTH ↓ 24-hour Urine Cortisol (>3x normal) ↓ Dexamethasone Suppression Tests:

  • Low-dose (1 mg): No suppression
  • High-dose (8 mg): No suppression (vs. pituitary) ↓ ACTH Level:
  • ACTH >100 pg/mL suggests ectopic source
  • ACTH 50-100 pg/mL: Consider CRH stimulation test

[CLINICAL_PEARL] Extreme hypokalemia (<2.5 mEq/L) with severe metabolic alkalosis strongly suggests ectopic ACTH syndrome.

Malignancy Screening Protocol
SyndromePrimary MalignanciesRecommended Imaging
HypercalcemiaLung, kidney, head/neck, breastChest CT, abdominal CT
SIADHSmall cell lung cancer (75%)Chest CT with contrast
LEMSSmall cell lung cancer (50-60%)Chest CT, whole-body PET
CushingSCLC, pancreatic NET, carcinoidChest/abdominal CT, octreotide scan

[HIGH_YIELD] In patients >40 years with new-onset LEMS, cancer screening should be repeated every 6 months for 2 years if initial workup is negative.

Management focuses on symptom control while treating the underlying malignancy, as syndrome resolution typically parallels tumor response.

Hypercalcemia Management

Acute Management Algorithm:

Severe Hypercalcemia (>12 mg/dL or symptomatic) ↓

  1. IV Normal Saline 200-500 mL/hr (Goal: 2-4 L in 24 hours if tolerated) ↓
  2. Bisphosphonates:
    • Zoledronic acid 4 mg IV (preferred)
    • Pamidronate 60-90 mg IV ↓
  3. Additional agents if refractory:
    • Calcitonin 4-8 U/kg SQ q12h (rapid onset, short duration)
    • Denosumab 120 mg SQ (if bisphosphonate contraindicated)

[CLINICAL_PEARL] Zoledronic acid is preferred over pamidronate due to shorter infusion time (15 minutes vs. 2-4 hours) and superior efficacy.

Chronic Management:

  • Cinacalcet 30-90 mg BID for persistent elevation
  • Denosumab 120 mg SQ monthly for bone-predominant disease
  • Avoid thiazide diuretics, calcium supplements, vitamin D
SIADH Treatment

Treatment Approach by Severity:

SeveritySodium LevelTreatment
Mild130-134 mEq/LFluid restriction 1-1.5 L/day
Moderate125-129 mEq/LFluid restriction + salt tablets
Severe<125 mEq/L3% hypertonic saline + vasopressin antagonists

Acute Severe Hyponatremia:

  • 3% NaCl at 1-2 mL/kg/hr
  • Target correction: 1-2 mEq/L/hr initially, then 0.5 mEq/L/hr
  • Maximum correction: 8 mEq/L in 24 hours (risk of osmotic demyelination)

Vasopressin Receptor Antagonists:

  • Tolvaptan 15-60 mg daily (oral)
  • Conivaptan 20 mg IV loading, then 20 mg/day (ICU only)

[HIGH_YIELD] Tolvaptan is contraindicated in patients with underlying liver disease due to hepatotoxicity risk.

LEMS Management

Symptomatic Treatment:

  • 3,4-Diaminopyridine (3,4-DAP) 10-20 mg TID (first-line)
    • Mechanism: Blocks voltage-gated potassium channels
    • Monitor for seizure risk
  • Pyridostigmine 60 mg TID-QID (adjunctive)
  • Guanidine 125-250 mg TID (alternative, limited by side effects)

Immunosuppressive Therapy:

  • Corticosteroids: Prednisone 1 mg/kg/day, taper over months
  • IVIG: 2 g/kg over 5 days for acute exacerbations
  • Plasma exchange: Reserved for severe, refractory cases
Ectopic Cushing Treatment

Acute Management:

Severe Hypercortisolism ↓

  1. Ketoconazole 400-1200 mg/day (Rapid onset, hepatotoxicity monitoring) ↓
  2. Add Metyrapone 250-500 mg q6h (if inadequate response) ↓
  3. Consider Mifepristone 300-1200 mg/day (glucocorticoid receptor antagonist)

Supportive Care:

  • Hypokalemia correction: Aggressive potassium replacement
  • Diabetes management: Insulin therapy often required
  • Infection prophylaxis: Consider PCP prophylaxis if prolonged steroids
  • Psychiatric support: Monitor for severe depression/psychosis

[KEY_CONCEPT] Bilateral adrenalectomy may be considered for refractory cases when primary tumor is unresectable, though this requires lifelong steroid replacement.

Primary Tumor Treatment: Definitive management requires treating the underlying malignancy according to NCCN guidelines. Response of paraneoplastic syndrome often serves as a biomarker for treatment efficacy.

Paraneoplastic syndromes can cause life-threatening complications requiring vigilant monitoring and prompt intervention.

Hypercalcemia Complications

Acute Complications:

  • Cardiac arrhythmias: Shortened QT interval, heart block, asystole
  • Nephrogenic diabetes insipidus: Severe dehydration, AKI
  • Neurologic: Coma, seizures (calcium >15 mg/dL)
  • Peptic ulcer disease: Increased gastric acid secretion

Monitoring Parameters:

  • Calcium levels: Daily during acute treatment
  • Renal function: Creatinine, BUN, electrolytes
  • Volume status: Daily weights, fluid balance
  • ECG monitoring: QT interval assessment

[CLINICAL_PEARL] Calcium levels should be corrected for albumin: Corrected Ca = Measured Ca + 0.8 × (4.0 - Albumin)

SIADH Complications

Osmotic Demyelination Syndrome:

  • Risk factors: Chronic hyponatremia, alcoholism, malnutrition
  • Clinical features: Quadriplegia, pseudobulbar palsy, altered consciousness
  • Prevention: Avoid correction >8-10 mEq/L in 24 hours

Monitoring Protocol:

  • Sodium levels: Every 2-4 hours during active correction
  • Neurologic status: Frequent assessments
  • Fluid balance: Strict intake/output monitoring
  • Urine osmolality: Trend to assess treatment response
LEMS Complications

Respiratory Failure:

  • Prevalence: 20-30% of patients during exacerbations
  • Risk factors: Concurrent infections, medications affecting NMJ
  • Management: Mechanical ventilation may be required

Autonomic Dysfunction:

  • Cardiovascular: Orthostatic hypotension, arrhythmias
  • Gastrointestinal: Severe constipation, ileus
  • Genitourinary: Urinary retention

Long-term Monitoring:

  • Pulmonary function tests: FVC, NIF every 6 months
  • Functional assessments: ADL scales, ambulation status
  • Cancer surveillance: Ongoing screening for SCLC
Ectopic Cushing Complications

Metabolic Crisis:

  • Severe hypokalemia: Paralysis, rhabdomyolysis, cardiac arrest
  • Hyperglycemic emergencies: DKA, HHS
  • Opportunistic infections: Increased infection risk

Cardiovascular Complications:

  • Hypertensive crisis: Malignant hypertension
  • Heart failure: Volume overload, cardiomyopathy
  • Thromboembolism: Hypercoagulable state

Monitoring Intensive Care:

ParameterFrequencyTarget/Goal
Cortisol (24h urine)Weekly<3x normal
PotassiumDaily>3.5 mEq/L
Glucoseq6h<200 mg/dL
Blood pressureContinuous<160/100 mmHg
Mental statusq4hAlert, oriented

[HIGH_YIELD] Steroid psychosis occurs in 50% of patients with ectopic Cushing syndrome and may require antipsychotic medications.

Treatment Response Monitoring

Biomarkers of Treatment Response:

  • PTHrP levels: Hypercalcemia monitoring
  • Sodium normalization: SIADH treatment efficacy
  • CMAP amplitude: LEMS neurologic improvement
  • Cortisol levels: Cushing syndrome control

Cancer Treatment Integration: Paraneoplastic syndrome response often parallels tumor response to systemic therapy. Lack of biochemical improvement may indicate:

  • Treatment resistance: Need for alternative therapies
  • Disease progression: Additional staging required
  • Secondary causes: Non-paraneoplastic etiology consideration

[KEY_CONCEPT] Syndrome recurrence during cancer treatment often predicts disease progression before radiographic evidence.

Prognosis of paraneoplastic syndromes correlates strongly with underlying malignancy stage and treatment response, though syndrome-specific factors also influence outcomes.

Prognostic Factors by Syndrome

Hypercalcemia of Malignancy:

  • Median survival: 1-3 months from diagnosis
  • Poor prognostic factors: Calcium >13 mg/dL, renal dysfunction, solid tumors
  • Better outcomes: Hematologic malignancies, PTHrP-mediated vs. osteolytic
  • Response rate: 70-80% to bisphosphonates within 48-72 hours

SIADH:

  • Syndrome resolution: 60-70% with successful cancer treatment
  • Chronic management: May require long-term fluid restriction
  • Functional outcomes: Generally good with adequate sodium control
  • Recurrence rate: 30-40% with cancer progression

Lambert-Eaton Myasthenic Syndrome:

  • Cancer-associated: 5-year survival 20-30% (driven by SCLC prognosis)
  • Non-cancer LEMS: Near-normal life expectancy
  • Functional improvement: 60-80% with immunotherapy
  • Remission rates: 40% achieve sustained remission with cancer treatment

[CLINICAL_PEARL] Early-stage SCLC detected through LEMS screening has better prognosis than advanced disease, emphasizing the importance of comprehensive malignancy workup.

Ectopic Cushing Syndrome:

  • Overall prognosis: Poor, median survival 6-12 months
  • Syndrome control: Achieved in 60-70% with medical management
  • Tumor type impact: Pancreatic NETs have better outcomes than SCLC
  • Morbidity: High due to metabolic complications
Long-term Management Strategies

Survivorship Care Plans:

Cancer Remission Achieved ↓ Syndrome Assessment:

  • Complete resolution → Routine surveillance
  • Partial resolution → Continued targeted therapy
  • Persistent syndrome → Evaluate for residual disease ↓ Long-term Monitoring:
  • Syndrome-specific biomarkers q3-6 months
  • Functional assessments
  • Cancer surveillance per NCCN guidelines

Hypercalcemia Survivorship:

  • Bone health: DEXA scans annually, vitamin D/calcium optimization
  • Renal function: Monitor for chronic kidney disease
  • Cardiovascular: Screen for persistent arrhythmias
  • Bisphosphonate duration: Continue 6-12 months post-remission

SIADH Long-term Care:

  • Sodium monitoring: Monthly levels for 6 months, then quarterly
  • Cognitive assessment: Screen for persistent deficits
  • Fluid management: Gradual liberalization as tolerated
  • Drug interactions: Avoid medications that worsen SIADH

LEMS Rehabilitation:

  • Physical therapy: Strength training, mobility optimization
  • Occupational therapy: ADL adaptation strategies
  • Respiratory monitoring: Annual PFTs if history of weakness
  • Immunosuppression tapering: Gradual reduction over 1-2 years

Cushing Syndrome Recovery:

  • Adrenal insufficiency: May require temporary steroid replacement
  • Metabolic monitoring: Diabetes, hypertension management
  • Bone density: Screen for osteoporosis, fracture risk
  • Psychiatric care: Depression screening, cognitive rehabilitation
Quality of Life Considerations
SyndromeKey QOL IssuesInterventions
HypercalcemiaCognitive impairment, fatigueCalcium control, rehabilitation
SIADHMemory deficits, concentrationCognitive therapy, sodium optimization
LEMSMobility limitations, independencePhysical therapy, assistive devices
CushingBody image, mood disordersCounseling, support groups

[HIGH_YIELD] Syndrome recurrence is an early indicator of cancer relapse, often preceding radiographic evidence by weeks to months.

Follow-up Protocols

Standard Surveillance Schedule:

  • Months 1-6: Monthly syndrome-specific labs
  • Months 6-24: Quarterly assessments
  • Years 2-5: Biannual monitoring
  • Beyond 5 years: Annual screening

Red Flag Symptoms for Recurrence:

  • Hypercalcemia: Confusion, polyuria returning
  • SIADH: Progressive hyponatremia
  • LEMS: Increasing weakness, autonomic symptoms
  • Cushing: Metabolic decompensation, mood changes

[KEY_CONCEPT] Multidisciplinary care involving oncology, endocrinology, neurology, and supportive care teams optimizes outcomes for patients with paraneoplastic syndromes.

The integration of paraneoplastic syndrome management with cancer care requires ongoing coordination between specialists, with syndrome response serving as both a treatment goal and prognostic indicator.

!

High-Yield Key Points

1

Paraneoplastic syndromes may precede cancer diagnosis and serve as biomarkers for treatment response and disease progression

2

PTH suppression with elevated PTHrP distinguishes malignancy-associated hypercalcemia; zoledronic acid is first-line treatment

3

SIADH requires careful sodium correction (<8-10 mEq/L per 24 hours) to prevent osmotic demyelination syndrome

4

Lambert-Eaton syndrome shows post-exercise facilitation and proximal weakness; 50-60% are associated with small cell lung cancer

5

Ectopic Cushing syndrome presents with severe hypokalemia and lacks classic cushingoid features due to rapid progression

6

Syndrome resolution typically parallels tumor response to therapy, making these conditions important prognostic indicators

7

Multidisciplinary management focusing on both syndrome control and underlying malignancy treatment optimizes patient outcomes

References (7)

[1]

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Neuroendocrine and Adrenal Tumors. 2023.

[2]

Stewart AF. Clinical practice. Hypercalcemia associated with cancer. N Engl J Med. 2005;352(4):373-379.

PMID: 15673803
[3]

Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15(4):391-404.

PMID: 26906964
[4]

Verbalis JG, Goldsmith SR, Greenberg A, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med. 2013;126(10 Suppl 1):S1-42.

PMID: 24074529
[5]

Titulaer MJ, Lang B, Verschuuren JJ. Lambert-Eaton myasthenic syndrome: from clinical characteristics to therapeutic strategies. Lancet Neurol. 2011;10(12):1098-1107.

PMID: 22094129
[6]

Nieman LK, Biller BM, Findling JW, et al. Treatment of Cushing's syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(8):2807-2831.

PMID: 26222757
[7]

Peters H, et al. ALEX trial: Alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. N Engl J Med. 2017;377(9):829-838.

PMID: 28586279

Related Oncology Articles

O
Lung Cancer: NSCLC and SCLC — Screening, Staging, and Targeted Therapy
9 minintermediate
O
Colorectal Cancer: Screening, Staging, and Systemic Therapy
8 minintermediate
O
Prostate Cancer — PSA Screening, Active Surveillance, and ADT
7 minintermediate
Practice Oncology Questions →

Free Board Exam Preparation

Access 1000+ clinical vignettes, adaptive quizzes, spaced repetition, and more review articles — completely free.

Sign Up Free

Discussion & Reviews

Sign in to join the discussion
Loading comments...
← Back to Knowledge Library